Category: Middle East and North Africa

May 17, 2017 Off

Sobi’s hereditary tyrosinemia drug approved in Saudi Arabia

By Dino Mustafić

The Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules in all strengths (2 mg, 5 mg, 10 mg and 20 mg) for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.